Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Go back to Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis| ALKERMES (NASDAQ: ALKS) | Delayed: 46.71 +0.64 (1.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.07 | 52 Week High | $80.71 | |||
| Open | $47.10 | 52 Week Low | $27.14 | |||
| Day High | $47.40 | P/E | 359.31 | |||
| Day Low | $46.41 | EPS | $0.13 | |||
| Volume | 1,423,623 | |||||
